Arrowhead Pharmaceuticals, Inc. (LON:0HI3)
London
· Delayed Price · Currency is GBP · Price in USD 15.96
+0.40 (2.54%)
At close: Jun 27, 2025
Arrowhead Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | 2015 - 2019 |
| 545.21 | 3.55 | 240.74 | 243.23 | 138.29 | 87.99 | Upgrade
| |
Revenue Growth (YoY) | 1436.97% | -98.52% | -1.03% | 75.89% | 57.16% | -47.87% | Upgrade
|
Gross Profit | 545.21 | 3.55 | 240.74 | 243.23 | 138.29 | 87.99 | Upgrade
|
Selling, General & Admin | 133.53 | 124.54 | 108.82 | 132.44 | 85.44 | 54 | Upgrade
|
Research & Development | 530.24 | 480.09 | 336.92 | 289.3 | 201.88 | 127.15 | Upgrade
|
Operating Expenses | 663.76 | 604.63 | 445.74 | 421.74 | 287.32 | 181.15 | Upgrade
|
Operating Income | -118.55 | -601.08 | -205 | -178.51 | -149.04 | -93.16 | Upgrade
|
Interest Expense | -63.03 | -32.35 | -18.33 | - | - | - | Upgrade
|
Interest & Investment Income | 30.89 | 22.72 | 15.3 | 5.03 | 6.12 | 9.19 | Upgrade
|
Other Non Operating Income (Expenses) | -1.58 | -1.75 | 1.54 | 0.77 | 2.07 | -0.6 | Upgrade
|
EBT Excluding Unusual Items | -152.27 | -612.46 | -206.49 | -172.71 | -140.85 | -84.57 | Upgrade
|
Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.02 | Upgrade
|
Pretax Income | -152.27 | -612.46 | -206.49 | -172.71 | -140.85 | -84.55 | Upgrade
|
Income Tax Expense | 2.4 | -2.77 | 2.78 | 3.79 | 0 | 0 | Upgrade
|
Earnings From Continuing Operations | -154.68 | -609.69 | -209.28 | -176.49 | -140.85 | -84.55 | Upgrade
|
Minority Interest in Earnings | 10.71 | 10.2 | 4 | 0.43 | - | - | Upgrade
|
Net Income | -143.97 | -599.49 | -205.28 | -176.06 | -140.85 | -84.55 | Upgrade
|
Net Income to Common | -143.97 | -599.49 | -205.28 | -176.06 | -140.85 | -84.55 | Upgrade
|
Shares Outstanding (Basic) | 127 | 120 | 107 | 105 | 104 | 101 | Upgrade
|
Shares Outstanding (Diluted) | 127 | 120 | 107 | 105 | 104 | 101 | Upgrade
|
Shares Change (YoY) | 13.90% | 12.21% | 1.26% | 1.62% | 3.00% | 2.14% | Upgrade
|
EPS (Basic) | -1.14 | -5.00 | -1.92 | -1.67 | -1.36 | -0.84 | Upgrade
|
EPS (Diluted) | -1.14 | -5.00 | -1.92 | -1.67 | -1.36 | -0.84 | Upgrade
|
Free Cash Flow | 9.6 | -604.32 | -330.63 | -188.91 | 147.75 | -107.75 | Upgrade
|
Free Cash Flow Per Share | 0.08 | -5.04 | -3.10 | -1.79 | 1.42 | -1.07 | Upgrade
|
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
Operating Margin | -21.75% | -16927.06% | -85.16% | -73.39% | -107.77% | -105.87% | Upgrade
|
Profit Margin | -26.41% | -16882.37% | -85.27% | -72.39% | -101.85% | -96.09% | Upgrade
|
Free Cash Flow Margin | 1.76% | -17018.31% | -137.34% | -77.67% | 106.84% | -122.46% | Upgrade
|
EBITDA | -97.43 | -582.49 | -192.51 | -168.09 | -140.77 | -87.22 | Upgrade
|
EBITDA Margin | -17.87% | - | -79.97% | -69.11% | -101.79% | -99.12% | Upgrade
|
D&A For EBITDA | 21.13 | 18.6 | 12.49 | 10.42 | 8.27 | 5.94 | Upgrade
|
EBIT | -118.55 | -601.08 | -205 | -178.51 | -149.04 | -93.16 | Upgrade
|
EBIT Margin | -21.75% | - | -85.16% | -73.39% | -107.77% | -105.87% | Upgrade
|
Updated Feb 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.